BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32771446)

  • 21. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    Hinata N; Hussein AA; George S; Trump DL; Levine EG; Omar K; Dasgupta P; Khan MS; Hosseini A; Wiklund P; Guru KA
    BJU Int; 2017 Apr; 119(4):605-611. PubMed ID: 27743481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
    Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
    Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
    Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
    Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study.
    Møller CT; Støer NC; Blindheim A; Berge V; Tafjord G; Fosså SD; Andreassen BK
    BMC Cancer; 2022 Dec; 22(1):1301. PubMed ID: 36510166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
    Li R; Naidu S; Fan W; Rose K; Huelster H; Grass GD; Vosoughi A; Dhillon J; Kim Y; Gupta S; Jain RK; Zhang J; Zemp L; Yu A; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Sexton WJ
    Urol Oncol; 2023 Nov; 41(11):457.e17-457.e24. PubMed ID: 37880002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
    Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
    Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
    Körner SK; Dreyer T; Carus A; Dohn LH; Joensen UN; Lam GW; Jensen NV; Fabrin K; Jensen TK; Pappot H; Agerbæk M; Jensen JB
    Scand J Urol; 2024 Feb; 59():39-46. PubMed ID: 38406925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England.
    John JB; Varughese MA; Cooper N; Wong K; Hounsome L; Treece S; McGrath JS; Harden S
    Eur Urol Focus; 2021 Mar; 7(2):359-365. PubMed ID: 32088138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    Lemiński A; Kaczmarek K; Byrski T; Słojewski M
    PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort.
    Aziz A; May M; Burger M; Palisaar RJ; Trinh QD; Fritsche HM; Rink M; Chun F; Martini T; Bolenz C; Mayr R; Pycha A; Nuhn P; Stief C; Novotny V; Wirth M; Seitz C; Noldus J; Gilfrich C; Shariat SF; Brookman-May S; Bastian PJ; Denzinger S; Gierth M; Roghmann F;
    Eur Urol; 2014 Jul; 66(1):156-63. PubMed ID: 24388438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.